Dry powder formulations of epinephrine and associated methods
Inventors
Lyman, Scott • Bleske, Barry • Lanpher, Ted William
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
Provided herein are dry powder formulations comprising epinephrine alone or in combination with at least one enabling agent suitable for nasal application. Also provided are unit dose forms and devices comprising such formulations and methods of using such formulations for the treatment of various conditions including anaphylaxis, anaphylactoid reaction, respiratory conditions, hemodynamic collapse, and for administration during cardiopulmonary arrest and other life-threatening conditions.
Core Innovation
The invention relates to intranasal dry-powder pharmaceutical compositions for administration of epinephrine or a pharmaceutically acceptable salt thereof. The compositions include a non-sulfite stabilizer and a carrier, and are formulated as a dry powder suitable for intranasal delivery using a reservoir and a means for discharging one or more doses. The disclosed dose for epinephrine is about 0.01 mg to about 10 mg per dose, and the non-sulfite stabilizer is present in an amount of about 0.01% w/v to about 5% w/v, or about 0.01% w/v to about 2% w/v for a spray-dried powder embodiment.
The disclosed formulations do not include an alpha-adrenergic blocker. The invention addresses intranasal epinephrine formulation without needles while improving stability compared with aqueous formulations and sulfite-containing products. It emphasizes enabling systemic absorption through intranasal delivery while avoiding alpha-adrenergic blockers.
The invention further includes device and kit concepts for intranasal administration and storage. The device includes a reservoir and discharge means, with optional features including sensing for displacement or deformation during dry powder dispensing, and electronics for actuation timing and wireless notifications. The kit includes at least one intranasal device enclosed in a pouch and/or a hard case, with optional packaging features for humidity, light, and oxygen protection, desiccant, water resistance or waterproofing, and MOLLE-compatible options.
Claims Coverage
The provided material identifies three independent claims covering reservoir-based intranasal delivery of dry-powder or spray-dried epinephrine formulations, with specified dose and stabilizer ranges, a carrier, and explicit exclusion of alpha-adrenergic blockers. The kit claim adds enclosure of the intranasal device in a pouch and/or hard case.
Reservoir-based intranasal dry-powder epinephrine formulation excluding alpha-adrenergic blockers
An intranasal device having a reservoir and a means for discharging one or more doses, wherein the reservoir contains a dry powder pharmaceutical composition comprising epinephrine or a pharmaceutically acceptable salt thereof at about 0.01 mg to about 10 mg per dose, a non-sulfite stabilizer at about 0.01% w/v to about 5% w/v, and a carrier, and wherein the pharmaceutical composition does not include an alpha-adrenergic blocker.
Kit enclosure for intranasal dry-powder epinephrine formulation excluding alpha-adrenergic blockers
A kit for intranasal administration including at least one intranasal device with a reservoir and a means for discharging one or more doses, wherein the reservoir contains a quantity of a dry powder pharmaceutical composition comprising epinephrine or a pharmaceutically acceptable salt thereof at about 0.01 mg to about 10 mg per dose, a non-sulfite stabilizer at about 0.01% w/v to about 5% w/v, and a carrier, wherein the composition does not include an alpha-adrenergic blocker, and wherein the at least one intranasal device is enclosed in a pouch and/or a hard case.
Reservoir-based intranasal spray-dried powder epinephrine formulation excluding alpha-adrenergic blockers
An intranasal device having a reservoir and a means for discharging one or more doses, wherein the reservoir contains a spray-dried powder pharmaceutical composition comprising epinephrine or a pharmaceutically acceptable salt thereof at about 0.01 mg to about 10 mg per dose, a non-sulfite stabilizer at about 0.01% w/v to about 2% w/v, and a carrier, and wherein the pharmaceutical composition does not include an alpha-adrenergic blocker.
The independent claims collectively cover intranasal reservoir-based delivery of epinephrine in dry or spray-dried powder form with specified dose and non-sulfite stabilizer ranges, together with a carrier and explicit exclusion of alpha-adrenergic blockers. The kit claim adds enclosure of the intranasal device in a pouch and/or hard case.
Stated Advantages
Improved stability compared with aqueous and sulfite-containing products.
Avoidance of alpha-adrenergic blockers.
Needle-free intranasal administration using a dry-powder formulation.
Documented Applications
Intranasal administration of epinephrine using a dry-powder intranasal delivery device and a kit with pouch and/or hard case enclosure.
Interested in licensing this patent?